Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide

Abstract Background Glioblastoma (GB) is the most aggressive of all primary brain tumours and due to its highly invasive nature, surgical resection is nearly impossible. Patients typically rely on radiotherapy with concurrent temozolomide (TMZ) treatment and face a median survival of ~ 14 months. Al...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Craig A. Vincent, Itzel Nissen, Soran Dakhel, Andreas Hörnblad, Silvia Remeseiro
Format:	Article
Language:	English
Published:	BMC 2023-10-01
Subjects:	EGFR Enhancer Glioblastoma Epigenomic perturbation CRISPR/Cas9
Online Access:	https://doi.org/10.1186/s12885-023-11418-9